Clinical trial
Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and…
NCT00263042 · Sanofi, Industry · Terminated
Key facts
| NCT number | NCT00263042 |
|---|---|
| Title | Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes |
| Official title | Randomized, Multinational, Multicenter, Double-blind, Placebo-controlled, Two-arm Parallel Group Trial of Rimonabant 20 mg OD for Reducing the Risk of Major Cardiovascular Events in Abdominally Obese Patients With Clustering Risk Factors |
| Acronym | CRESCENDO |
| Lead sponsor | Sanofi, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Cardiovascular Disease |
| Intervention type | Drug |
| Interventions | Rimonabant, Placebo (for Rimonabant) |
| Enrollment | 18,695 |
| Start date | Dec 1, 2005 |
| Primary completion | Apr 1, 2009 |
| Completion | Apr 1, 2009 |
| First posted | Dec 7, 2005 |
| Last update posted | May 20, 2016 |
| Countries | Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czechia, Denmark, Finland and 31 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: